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Inhibitors of Apoptosis Proteins (IAPs) are a class of highly conserved proteins predominantly known for the regulation of
caspasesandimmunesignaling.However,recentevidencesuggestsacrucialroleforthesemoleculesintheregulationoftumor
cell shape and migration by controlling MAPK, NF-jB and Rho GTPases. IAPs directly control Rho GTPases, thus regulating
cell shape and migration. For instance, XIAP and cIAP1 function as the direct E3 ubiquitin ligases of Rac1 and target it for
proteasomal degradation. IAPs are differentially expressed in tumor cells and have been targeted by several cancer therapeutic
drugs that are currently in clinical trials. Here, we summarize the current knowledge on the role of IAPs in the regulation of cell
migration and discuss the possible implications of these observations in regulating tumor cell metastases.
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Facts
  IAPs directly regulate cell shape, migration and tumor
metastases.
  IAPs have pro- and anti-migratory roles depending on the
cellular context.
  IAPs can regulate the plasticity of tumor cell migration
by affecting the stability and activation of Rho GTPases.
  IAPs have been correlated with both negative and positive
tumor prognosis.
Open Questions
  What is the role of IAPs in regulating physiological forms
of cell migration like wound healing?
  What are the distinct roles of different IAPs in tumor
metastasis?
  What are the various signaling pathways activated by
IAP antagonists in the context of tumor cell invasion?
Inhibitor of Apoptosis Proteins (IAPs)
Inhibitor of apoptosis proteins (IAPs), also known as BIRCs
(BIR domain containing proteins) are a class of proteins
characterized by the presence of Baculovirus IAP Repeat
(BIR) domain, a Zn
2+ ion coordinating protein–protein
interaction motif. They are highly conserved from viruses
to mammals and were discovered in a genetic screen
of baculoviral genome as inhibitors of host programmed
cell death machinery, hence named IAPs.
1,2 However, recent
advances in the ﬁeld of IAP/BIRC biology strongly establish
these proteins to be pivotal for numerous cellular signaling
networks. Studies from other organisms down the evolu-
tionary ladder have also revealed that IAPs are pleotropic
proteins and not just inhibitors of caspases. Certain prokar-
yotes, yeasts and plants undergo a form of programmed cell
death(PCD)bycaspasehomologsknownasmetacaspases.
3
Yet no IAP homologs are found in prokaryotes and plants;
and metacaspasesare also notessential forprokaryotic PCD.
In case of S. cerevisiae, the only known IAP, BIR1p inhibits
apoptosis in a YCA1 (S. cerevisiae metacaspase)-indepen-
dent manner. BIR1p is required for proper chromosome
segregation and cytokinesis and moreover, YCA1 also has
roles in cell cycle regulation, clearance of protein aggregates,
and so on.
4–6 Further, though there are viral IAP homologs,
caspase homologs have not been identiﬁed in viruses.
1,2
There are eight known mammalian IAPs/BIRCs (Figure 1):
BIRC1 (neuronal IAP/NAIP), BIRC2 (cellular IAP1/cIAP1/
HIAP2), BIRC3 (cellular IAP2/cIAP2/HIAP1), BIRC4 (X-linked
IAP/XIAP/hILP), BIRC5 (Survivin), BIRC6 (BIR containing
ubiquitin conjugating enzyme/BRUCE/Apollon), BIRC7
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www.nature.com/cddis(Melanoma IAP/ML-IAP/Livin) and BIRC8 (IAP-like protein 2/
hILP2/Ts-IAP). Apart from the BIR domains, there are various
other structural motifs deﬁning the characteristics of IAPs.
NAIP has a NACHT domain and leucine-rich repeats
(LRR) implicated in Nod-like receptor (NLR)-mediated innate
immunity signaling.
7 Another important domain is the really
interesting new gene (RING) domain present in cIAP1, cIAP2,
XIAP, ML-IAP and hILP2. This domain provides an E3
ubiquitin ligase activity to the proteins by virtue of which, it
can promote attachment of monomeric ubiquitin or ubiquitin
chains of various kinds to the substrate. RING domains of
IAPs have been shown to be responsible for auto-ubiquitina-
tion, cross-ubiquitination of other IAPs and substrate
ubiquitination. cIAP1, cIAP2, XIAP and hILP2 also have an
ubiquitin-associated domain (UBA).
8,9 UBA domain binds to
monomeric ubiquitin as well as ubiquitin chains helping in
protein complex assembly to promote various cell signaling
events.
10 BRUCE lacks both the RING as well as UBA
domains but has an ubiquitin conjugation or UBC domain
catalyzing the conjugation of ubiquitin to the substrate. cIAP1
and cIAP2 have a CARD domain (CAspase Recruitment
Domain), which is also present in various components of
apoptotic and inﬂammation signaling complexes like caspases
(-1/-2/-4/-5/-9and-13),Apaf-1,PIDD,RAIDD,NODsandRIP2.
TheroleofCARDdomain inIAPshasbeenunknown,though a
recent study suggested its role in autoinhibition of the RING
domain activity of cIAP1
11 (Figure 1).
As stated above, IAPs can be regulated by auto-ubiquitina-
tion and cross-ubiquitination via their RING domains. It has
been reported that loss of one IAP leads to an increase in the
protein levels of another IAP.
12 Further, the RING domain of
cIAP1 has been reported to mediate the degradation of other
RING-bearing IAPs.
13 In these lines, IAPs have been shown
to exist as heteromeric complexes in the cytosol of many
humancelllines.
14Further,aheteromericcomplexofsurivivin
and XIAP has been shown to resist apoptosis.
15 IAPs can
also be regulated by certain endogenous inhibitors of
IAPs like Smac/DIABLO, Omi/HtrA2, XAF1, ARTS and
TWEAK.
16–20 Smac/DIABLO, the most well-studied IAP
inhibitor is a mitochondrial protein released into the cytosol
during apoptotic induction. Upon release into the cytosol,
Smac/DIABLO binds directly to XIAP by its N-terminal,
IAP-binding motif (IBM). IBM interacts with BIR2 and
BIR3 of XIAP, and thereby disrupts the function of XIAP to
block caspase-3, -7, and -9.
21 Smac has also been shown




IAPs have come forth as vital signaling molecules at the
crux of various cell death and survival pathways. Apart from
apoptotic-caspase cascade, IAPs are essential modulators
of innate immunity signaling, canonical and non-canonical
NF-kB pathways as well as TGFb signaling pathway
23
(Figure 2). Their role as tumor modulators has been
substantiated by differential expression of IAP family mem-
bers in various malignancies. Elevated expression of IAPs in
certain tumor types has been correlated with tumor survival
and resistance to chemotherapy. So, a variety of antitumor
therapeutics, especially small-molecule inhibitors against
IAPs (IAP antagonist compounds (IAC), Smac mimetics) are
being designed and clinically tested.
24,25 Though several
studies have demonstrated elevated levels of multiple IAPs in
an array of human cancers as well as tumor models, a clinical
correlation could not be established for many of them.
Furthermore, the relative contribution of individual IAPs
towards tumorigenesis and progression is far from clear.
There have been opposing prognostic implications for IAPs in
different tumor types, strongly suggesting that the role of IAPs
in tumorigenesis is context- and cell type-dependent.
Role of IAPs in Tumorigenesis and Tumor Progression
IAPs correlated with negative prognosis. IAPs are
overexpressed in a number of tumors and are recognized
Figure 1 Domain architecture of mammalian IAPs. (a) A prototypical IAP is
depictedconsistingofTypeIandTypeIIBIRdomains,ubiquitin-bindingdomainand
RING domain with their functions and molecular structures. (b) Various mammalian
IAPs are depicted with their known functional domains. BIR, baculoviral IAP
repeat domain; NACHT/NOD, nucleotide binding and oligomerization domain;
LRR, leucine-rich repeats; UBA, ubiquitin-associated domain; CARD, caspase
recruitment domain; RING, really interesting new gene domain; UBC, ubiquitin
conjugating domain
Figure 2 Cellular phenotypes mediated by IAP–IAP complexes. Depicted are
the known cellular phenotypes that are regulated by IAPs. IAPs can form
homomeric or hetermeric complexes within the cells and have a central role in
various cellular signaling pathways that can be translated to various phenotypes
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Cell Death and Diseaseto regulate carcinogenesis at various stages. cIAP1 and
cIAP2 have been suggested as proto-oncogenes by various
genetic studies. cIAP1/2 and YAP (yes-associated protein)
are a part of 11q21–11q23 ampliﬁcations observed in a
variety of cancers like hepatocellular carcinoma, medullo-
blastoma, glioblastoma, gastric carcinoma, non-small cell
lung carcinoma and osteosarcoma.
26–29 Deletions of CARD
and RING domains in cIAP2 are linked to generation of an
oncoprotein in MALT (mucosa-associated lymphoid tissue)
lymphoma.
30 cIAP2, along with BAX and BMF has been
proposed as a three-gene signature for acute myeloid
leukemia (ALL) prognosis but there have been contrasting
reports for the importance of elevated levels of IAPs in other
forms of leukemias.
31–34 Elevated levels of IAPs in bladder
cancer and colorectal carcinoma correlated with progressive
stages of tumor as well as decreased overall patient
survival.
35–38 In breast carcinoma, higher nuclear expression
of XIAP correlated with lower patient survival.
39 Similarly, in
cervical squamous cell carcinoma, recurrence-free survival
rates were lower with high levels of nuclear cIAP1.
40
Furthermore, enhanced expression of survivin, cIAP1, cIAP2
and XIAP has been observed in chemotherapy-induced
multi-drug resistant multiple myeloma.
41 Apart from IAPs,
pro-apoptotic, endogenous IAP antagonists like Smac, Omi/
HtrA2, XAF1 and ARTS have also been characterized for
cancer prognosis.
42–45 Independent studies have shown that
patients expressing higher levels of Smac have higher
chances of recurrence-free survival in AML, breast cancer,
NSCLC, RCC, bladder carcinoma and colorectal carcinoma,
whereas lower levels have been associated with tumor
metastasis and lower life expectancy.
46–50 Studies with
XAF1 conﬁrmed its prognostic value in pancreatic cancer,
squamous cell lung cancer and ovarian cancer.
51,52 Low
expression levels of XAF1 could be correlated with disease
stage, differentiation status and lymph node metastasis in
squamous cell lung cancer patients.
53 Further, studies
carried out by Elhasid et al. found a loss of ARTS protein
expression in all malignant lymphoblasts in a majority of
pediatric ALL patients, which was found to be reversed upon
remission in almost all of them
54 (Table 1).
IAPs correlated with positive prognosis. There have
also been reports showing favorable cancer prognosis
with elevated levels of IAPs. In case of NSCLC, a study by
Ferreira et al.
55 reported that high XIAP levels correlated with
lower proliferation rate and longer patient survival, suggest-
ing it as a positive prognostic factor for NSCLC. Elevated
ML-IAP expression has been determined as an independent
favorable prognosis factor for pediatric ALL as well as
relapse-free survival in RCC.
56,57 In these lines, a recent
study by Lazar et al.
58 showed that high ML-IAP levels
correlated with poor prognosis in patients that responded
to an autologous melanoma vaccine. On the contrary, in
patients that remained with active disease after treatment
with melanoma vaccine, low to intermediate levels rather
than absence of protein is associated with favorable
prognosis due to paradoxical pro-apoptotic ML-IAP activ-
ity.
20,58 Furthermore, higher levels of IAPs (BIRC1-5) were
reported in prostate cancer cell lines as well as prostate
cancer samples without any clinical correlation.
59,60 How-
ever, some recent studies have identiﬁed XIAP expression
as an independent favorable prognostic marker for longer
relapse-free survival in prostate cancer patients (Table 2).
IAPs have been recently recognized as crucial regulators of
tumor cell migration and metastases.
61 We will be mainly
focusing further on IAP-mediated cellular migration in physio-
logical as well as patho-physiological context in this review.
Cell Migration
Migration is a complex and cell–type dependent fundamental
process that underlies key biological phenomena like tissue
formation and maintenance, regeneration as well as patholo-
gical conditions like cancer metastasis. While there are
Table 1 IAPs and negative prognosis
Cancer type IAPs involved Detection parameter References
IAPs and negative prognosis
Esophageal squamous cell carcinoma cIAP1 and cIAP2 Genomic DNA and RNA (11q21–23 amplicon) Imoto et al.
119
SCLC and NSCLC cIAP1 and cIAP2 Genomic DNA and Protein (11q21–23 amplicon) Dai et al.
27
Hepatocellular carcinoma cIAP1 Genomic DNA and RNA (11q21–23 amplicon) Zender et al.
29
MALT lymphoma cIAP2 RNA (t(11:18)(q21:21) translocation) Dierlamm et al.
120
Acute myeloid leukemia (ALL) cIAP2 RNA Hess et al.
33
Bladder cancer XIAP Protein and RNA Li et al.
36
Nuclear cIAP1 Protein Che et al.
38
Colorectal cancer XIAP RNA and protein Xiang et al.
37
cIAP2 Protein Krajewska et al.
35
Breast cancer Nuclear XIAP Protein Zhang et al.
39
Cervical sqamous cell carcinoma Nuclear cIAP1 Protein (resistance to radiotherapy) Imoto et al.
40
Various IAPs reported to be upregulated in cancers and/or linked to negative tumor prognosis are listed






IAPs and positive prognosis







Pediatric ALL ML-IAP RNA and protein Choi et al.
56
Melanoma ML-IAP Protein Lazar et al.
58
Prostate cancer XIAP Protein Seligson
et al.
60
Various IAPs reported to be downregulated in cancers and/or linked to positive
tumor prognosis are listed
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Cell Death and Diseasevarious factors that inﬂuence cell shape and migration like
cell–cell and cell–matrix adhesions, pericellular proteolysis,
polarity, as well as the extracellular matrix (ECM), the basic
cellular feature that drives this process is the actin cytoske-
leton. Seminal work by Lauffenburger and Horwitz
62 in 1996
proposedaﬁve-stepprocessforcellmigration.Theprocessof
cell migration begins with protrusions formed by cell at the
leading edge in response to an appropriate migration
stimulus. This leads to the formation of focal adhesion (FA)
complexes that help attach the cell to the ECM. In the event of
secretion of proteases, matrix degradation occurs at the
leading edge of the cell. This is followed by actomyosin
contractility and ﬁnally the detachment of the rear end of the
cell.
62 While most of the studies on cell migration were
performed in 2D matrices and substrates, recent studies with
3D matrices revealed that cells exploit a much greater range
of protrusive structures to migrate through these matrices like
ﬁlopodia and lobopodia.
63 This accounts for some of the
conﬂicting results obtained depending on the model system
selected to study cell migration. Therefore, care should be
taken to interpret the results from dissimilar model systems.
Owing to the integral role of the actin cytoskeleton in
migration of cells, Rho GTPases, which are known to regulate
many aspects of intracellular actin dynamics, have been
highly implicated in this process. Rho GTPases are a family of
20proteins,amongwhichRac1,RhoAandCdc42arethebest
studied. Seminal studies showed that each of these proteins
have a role in actin cytoskeleton rearrangement; Rac1 was
linked to the formation of lamellipodia, Cdc42 to ﬁlopodia and
RhoA to stress ﬁber formation by generation of actomyosin
contractility.
64
Cells can migrate as single cells or as a group in clusters,
sheets; this has led to the classiﬁcation of cell migration into
single-cell and collective cell migration. Single-cell migration
can further be divided into mesenchymal and amoeboid forms
of migration. Mesenchymal migration is characterized by an
elongated morphology, high attachment of cells to the ECM
via FA complexes, as well as secretion of proteases to
degrade the ECM. Amoeboid movement is largely indepen-
dent of cell–matrix contact and proteolytic degradation and
the cells show a rounded morphology. Rac1 and Cdc42
have an important role at the leading edge of the cell in
mesenchymal form of migration. Rac1 helps to initiate
lamellipodium formation and Cdc42 maintains the direction-
ality of the cell.
65,66 RhoA is usually detected at the trailing
edge of these cells where it facilitates in tail retraction. RhoA
has a more prominent role in amoeboid movement via
actomyosin contractility through myosin activation.
67,68
Cdc42 is also implicated in amoeboid migration and invasion
in melanoma cells.
69
While cells preferentially employ one of the above-
described migration types, they have the ability to adapt to
the changes in their microenvironment and switch from one
mode of migration to the other. Thus, plasticity of cell
migration has ample physiological and patho-physiological
relevance. Rho GTPases have an integral role in this switch,
with their activityoften correspondingtothe preferred mode of
migration of a particular cell type. For example, RhoA
activation is associated with amoeboid form of migration and
Rac1 with mesenchymal mode of migration, although RhoA-
mediated actomyosin contractility is also an essential compo-
nent of mesenchymal migration contributing to tail retraction.
Recent studies have also implicated other Rho GTPases in
these processes; RhoE, for example, is downregulated in
hepatocellular carcinoma and this is associated with poor
prognosis due to loss of E-Cadherin at junctions, thus leading
to tumor progression and metastasis.
70,71
Role of IAP-Mediated Signaling in Cell Migration
IAPs in physiological forms of migration. The ﬁrst
evidence for the role of IAPs in cell migration was
demonstrated by Geisbrecht and Montell in 2004 during their
studies with border cell migration in Drosophila ovaries, an
important phenomenon for oogenesis during embryonic
development. The process of border cell migration exem-
pliﬁes how cells of epithelial origin acquire migratory proper-
ties. They reported that expression of dominant-negative
Rac1 (Rac1-N17) in border cells inhibits border cell migra-
tion, and hence, renders the ﬂy infertile. Further, in a forward
genetics screen, they found that when overexpressed,
DIAP1 or Drosophila IAP1 can suppress Rac-N17-mediated
border cell migration defect. This effect was mediated by the
BIR domains of DIAP1 and was independent of its anti-
apoptotic activity as well as its RING domain.
72 Furthermore,
DIAP1 was found to interact with proﬁlin, an actin-binding
protein and binding partner for Rac1. This suggests a pro-
migratory role of DIAP1 in actin polymerization via proﬁlin to
mediate border cell migration in Drosophila ovaries. In these
lines, we have uncovered that XIAP and cIAP1 can function
as the direct E3 ubiquitin ligase of Rac1.
73 Loss of these two
IAPs stabilizes Rac1 and promotes an elongated-mesen-
chymal mode of migration in many primary and tumor cell
lines (discussed below). This observation is in contradiction
with the results found with DIAP1, but whether mammalian
IAPs can bind to proﬁlin and the physiological relevance of
this interaction still need to be tested.
In collaboration with Reinhard Ko ¨ster’s group, we have
shown a role for DrXIAP in migration of cerebellar granule
neurons (CGNs) during cerebellar development in Danio
rerio. We employed transgenic zebraﬁsh strain to generate
conditional expression of transgenes in the cells of the upper
rhombic lip. Enhanced expression of DrXIAP in CGNs lead to
a loss of cell polarity and cells were often found in the fourth
ventricle forming clusters. These effects were Rac1-depen-
dent as increasing the expression of wild-type Rac1 with
DrXIAP could rescue the phenotype.
73 Thus, DrXIAP shows
an anti-migratory effect on progenitor cell migration during
zebraﬁsh brain development by regulating Rac1. We also
observed that XIAP knockdown in immortalized cerebellar
granular cells derived from mice showed enhanced Rac1
levels, suggesting an evolutionarily conserved role for IAPs in
controlling Rac1 homeostasis.
IAPs have also been shown to modulate endothelial cell
migration. Kim et al.
74,75 found a role of XIAP in regulating
endothelial cell survival and migration. They found that
caveolin1 can bind to XIAP via its BIR3 domain, and thus,
recruits XIAP to a5–integrin complex. XIAP also recruits FAK
tothiscomplexandwasfoundtobeessentialforshear-stress-
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Cell Death and Diseaseinduced, Src-mediated Y567 phosphorylation of FAK and
ERK1/2 activation.
76 They also showed that XIAP could
directly bind to FAK via FRNK domain of FAK and promote
endothelial cell migration by inhibiting FRNK-mediated
cell adhesion.
77 As Rac1, FAK and integrins are vital to the
dynamics of all forms of cell adhesion and migration, it is
tempting to investigate the role of IAPs in other physiological
formsofcellmigrationincludingwoundhealingandinimmune
cell responses. IAPs were shown to exhibit both pro- and
anti-migratory functions in tumor cells, which have been
discussed below.
Pro-migratory effects of IAPs in tumor cells. A recent
study by Lopez et al.
11 suggested that CARD domain of
cIAP1 prevents its auto-ubiquitination through intramolecular
inhibition of RING dimerization and hence its E3 ubiquitin
ligase activity. They further showed that CARD-mediated
RING regulation had implications on cell proliferation and
migration. cIAP1 cooperates with Myc to drive cell prolifera-
tion by ubiquitination and degradation of myc antagonist,
Mad1. By means of reconstitution studies in cIAP1/2 DKO
MEFs they could observe more RING activity in CARD
deletion mutant of cIAP1 as compared with WT cIAP1. Using
the same strategy with scratch assays, they observed
enhanced migration in mutant cIAP1 reconstituted cells as
compared with WT cIAP1 cells. This suggests a role for
CARD domain in regulating cIAP1-mediated cell migration.
Furthermore, they demonstrated a loss of wound-healing
ability in MCF-7 cells upon cIAP1 knockdown, suggesting a
pro-migratory role of cIAP1 in these cells. Though this study
ﬁnds a role for CARD domains in regulation of RING activity
and migration, there have been other studies using IAC-
mediated degradation of cIAP1 that suggest a different
mechanism of regulation of cIAP1 stability. Report from
Blankenship et al.
8 using cIAP1 WT and its CARD deletion
mutant suggest that the linker region between BIR3
and CARD domain of cIAP1 and not the CARD domain
per se is important for modulating its stability. Studies by
Fairbrother et al.
24 suggest the role of BIR3–RING interac-
tions in the modulation of RING E3 ligase activity
of cIAP1.
78
Another study by Liu et al.
79 attempts to deﬁne the role of
XIAP–RING domain in cancer cell migration. It was shown
that depletion of XIAP in HCT116 colorectal carcinoma cells
leads to diminished migration in scratch assays and XIAP-
mediated cancer cell migration is RING domain-dependent.
The same group also determined a role for XIAP–RhoGDI
interactionviaRINGdomainofXIAPtomediatecellmotilityby
regulating actin cytoskeleton. XIAP was found to negatively
regulate RhoGDI sumoylation at Lys-138 to promote cancer
cell motility.
80,81
Anti-migratory effects of IAPs in tumor cells. There have
also been studies deﬁning the anti-migratory effects of IAPs
in tumor scenarios. We have shown that cIAP1, cIAP2, XIAP
and ML-IAP can promote proteasomal degradation of
C-RAF, a central kinase of the classical MAPK pathway that
plays an important role in tumorigenesis downstream of
Ras.
82,83 Knockdown of IAPs using siRNAs leads to
enhanced lamellipodia and ﬁlopodia formation in HeLa cells
as well as C-RAF-dependent enhanced cell migration.
Oncogenic Ras mutations occur in B30% of all human
cancers and C-RAF is pivotal to Ras signaling. C-RAF/MAPK
pathway activation can promote cell survival by regulating
expression/activity of BCL-2 family members.
84 C-RAF can
also directly restrain apoptosis by binding and inhibiting
stress-induced kinase ASK-1.
85 Furthermore, C-RAF can
promote EMT, tissue invasion and metastasis by production
of TGFb and inhibition of Rho effector, ROCK2.
86–88
Further work in these lines have demonstrated that knock-
downofIAPsusinganIACleadtoanelongatedmorphologyin
various primary and tumor cells as well as Rac1- and MAPK-
dependent enhanced migration in tumor cells. IAC-mediated
knockdown of IAPs can lead to Rac1 stabilization and
activation, leading to Rac1-dependent, enhanced mesen-
chymal-type of tumor migration
73,89 (Figure 3). This migration
phenotypecouldberecapitulatedbyemployingearlypassage
cIAP1
 /  as well as XIAP
 /  MEFs. Knockout MEFs
showed elongated morphology and migrated more efﬁciently
as compared with strain-matched WT MEFs in a Rac1-
dependent manner (Figure 3). Most of the discrepancy
observed with respect to pro- and anti-migratory effects of
IAPs could be attributed to the difference in the cell types
employed, as many of the migration-regulating molecules
controlled by IAPs could promote or inhibit migration in a
context-dependent manner.
Role of IAP-effector signaling in cell migration. The
phenotype observed in our studies upon IAP knockdown
using siRNAs and IACs resembles epithelial–mesenchymal
transition (EMT) in the cells.
73 EMT is an important cellular
program occurring both during embryonic development as
well as pathogenesis. Primary epithelial tumors can give rise
to dissemination of single carcinoma cells by undergoing
EMT, and thus, lead to tumor migration and metastasis.
90
Pertinent to this, it was previously demonstrated that
coordinated activation of Rac1 and the RAF/MAPK pathway
is required for cell scattering and migration, key components
of EMT upon activation of Ras in NBT II rat bladder
Figure 3 IAPsmodulatecellularmorphologyandmigration.Transientdepletion
ofIAPsusingsiRNAsandIACsaswellascIAP1andXIAPknockoutMEFsshowan
elongated mesenchymal-like morphology and mesenchymal mode of migration
(*indicates activation)
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Cell Death and Diseasecarcinoma cell line.
91 This is in line with our observations that
coordinated activation of both C-RAF and Rac1 pathways
leads to cell migration upon IAP depletion.
Apart from these reports, there have been various
instances demonstrating that these pathways potentiate
the effect of each other. A recent report describes that
ERK2, a downstream kinase of Ras-Raf-MEK-ERK pathway,
can directly phosphorylate components of WAVE2 complex,
WAVE2 and Abi1, essential for interaction of WAVE complex
with Arp2/3 and actin to mediate actin polymerization and
lamellipodia formation.
92 Rac1 is the direct activator of WAVE
complex and it is now shown that MAPK activation can
potentiate its effect. Conversely, Rac1 has been shown to
potentiate Ras-dependent skin tumor formation by hyperacti-
vation of MEK-ERK1/2 signaling by Rac1 effector, Pak1.
93
Furthermore, RacGEF Tiam1 has been implicated tumor
invasiveness and metastasis.
94–97 Rac1 activation can
promote both EMT and mesenchymal–epithelial transition
(MET) by regulating assembly and disassembly of adherens
junctions, and thereby has the ability to either prevent or
facilitate tumormetastasis and secondarytumor formation.
98–
100 Rac1 activity is also vital for microtubule-induced FA
disassembly for driving cell migration.
101 Further, as pre-
viously stated, tumor cell plasticity is a major contributor
towards metastasis. Rac1 activation drives mesenchymal
mode of migration, which limits lung colonization in mice.
102
Further, knockdown of IAPs can also lead to inactivation of
RhoA.
73 In addition, unpublished observations from our lab
reveal a direct interaction between IAPs and RhoA indepen-
dent of activation status of RhoA. Therefore, it necessitates a
careful examination of coordinated Rac1-RhoA signaling
pathways to predict the ﬁnal migration phenotype in IAP-
depleted cells (Figure 4).
Apart from C-RAF, Rac1 and RhoA, IAPs can also mediate
both canonical and non-canonical NF-kB pathways by
ubiquitinating RIP and NIK kinases, respectively, at the
interface of cell death/survival, inﬂammation and innate
immune response as recently reviewed.
23,24 NF-kB pathway
can be activated due to TNFa secreted by activated
macrophages, ﬁbroblasts, Kupffer cells and a variety of tumor
cells including breast carcinoma, colon carcinoma and B-cell
lymphoma. Induction of NF-kB and Akt signaling pathways by
TNFa secretion inhibits GSK-3b-mediated phosphorylation of
Snail and b-catenin, inducing their stabilization and nuclear
localization.
103,104 Snail can interact with b-catenin and
establish a positive feedback loop for Wnt-dependent
transcription.
105 Taken together, all the above signaling
events contribute to angiogenic activity, accelerated EMT
and tumor cell invasion and metastasis. NF-kB activation can
also directly promote tumor survival and metastases.
106–109 A
recent study demonstrated a role for IAP-mediated regulation
of non-canonical NF-kB signaling in modulating migration and
invasion in glioblastoma cells in a preclinical tumor model.
110
As IAPs can directly regulate the NF-kB pathway, they
can either promote or inhibit tumor invasion and metastasis in
a context-dependent manner. There has also been a report
by Baumann et al.
111 stating that C-RAF can synergize
with another kinase, MEKK1 to activate NF-kB pathway,
which adds to the intricacy of these signaling complexes
(Figure 4).
Conclusion and Future Perspectives
Cell migration studies suggest a context-dependent role of
IAPs in tumor cell migration. The ﬁnal test for lethality
associated with tumor is its metastatic potential or ability to
migrate from the site of primary tumor. Nearly 90% of tumor
lethality can be attributed to metastases. Therefore, it is vital
to determine the direct role of IAPs in tumor metastases.
Hwang et al.
112 examined the role of XIAP in prostate cancer
development using TRAMP (transgenic adenocarcinoma of
mouse prostate) model. They checked for the tumor growth
and metastatic potential in wild-type and XIAP-deﬁcient,
immunocompetent TRAMP mice and found that XIAP
deﬁciency led to an aggressive form of disease without any
compensatory increase in the levels of cIAP1 or cIAP2
levels.
112 Therefore, it can be surmised that though there are
elevated levels of XIAP in prostate cancers, it may not be
responsible for carcinogenesis and metastasis. Along similar
lines, another study was carried out by Mehrotra et al.
113 to
investigatethecombinedinﬂuenceofXIAPandSurvivinusing
amouse metastasis modelaswell as invitro matrigel invasion
assay. They injected tumor cells from two adenocarcinoma
cell lines, HCT116 (colorectal) and MCF-7 (breast) directly
into the spleen to check for liver metastasis in immunocom-
promised SCID mice. Using cell lines, either stably over-
expressing Survivin or having a stable knockdown of XIAP or
both, they could show a higher metastatic potential of injected
Figure 4 IAP-mediated signaling pathways involved in EMT/MET, cell
migration, invasion and metastases. Shown is the representation of various cellular
signaling pathways that are modulated by IAPs. IAPs regulate signal transduction
viaMAPK,RhoGTPase,NF-kBandseveralotherpathwaystomodulatethecellular
migration at endogenous levels as well as under tumor progression conditions.
Thecross talk betweenthese various pathwaysmight inﬂuencethe migratory ability
of the cells in a context-/cell–type-dependent manner (*denotes activation)
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IAPs.
113 Both the aforementioned studies are carried out in
mouse models with dissimilar background (immunocompe-
tent versus immunocompromised) using adenocarcinomas of
different origin as a basis for their study and showed
contrasting results on XIAP-mediated tumor metastasis.
This calls for further elucidation of pathways regulated by
IAPs under diverse patho-physiological conditions.
Further, tumor microenvironment is a complex concoction
of interacting factors and trying to mimic a human tumor
in vitro or using in vivo mouse models including genetically
engineered and humanized models might not be a true
representation of the scenario. Though mouse models have
contributed greatly to our current knowledge base and
treatment strategies, recapitulating the stochastic nature of
human tumorigenesis in a model organism is not completely
possible.
114 There are numerous examples of preclinically
successful drugs failing to deliver clinically leading to loss of
enormous amount of time, efforts and money. Therefore, it is
vital that we exercise caution while extrapolating results from
various tumor models.
IAPs are a part of complex signaling network, regulating
components responsible for a diverse array of migration
phenotypes. Deciphering the individual contribution of these
components for a particular context (cell type/tumor type/
stage) could determine the ﬁnal fate of the cell. Therefore, it is
also imperative that we recognize the underlying nature
of the pathology for appropriate use of IAP-mediated cancer
therapeutics. To improve the treatment efﬁcacy of IAP
antagonists, various combinatorial strategies for them
including chemotherapy and radiotherapy have been tested
pre-clinically.
24 For instance, beneﬁcial synergistic effects
wereobserved when IAP antagonists are used in combination
with death receptor agonists like TRAIL.
115 Apart from this,
recent study depicted combinatorial effect of Pak1, a down-
stream Rac effector, inhibition on IAP antagonist treatment in
NSCLC cell lines, rendering these cells hypersensitive to
apoptotic cell death.
116 Development of combination therapy
is being supported as it promotes better patient survival as
shown recently in a metastatic breast cancer Phase III clinical
trial.
117 Combination therapy might promote synergistic
effects leading to low drug dosage, as well as suppresses
resistance to therapy if multiple cell survival pathways are
targeted at once though there are chances of higher
toxicity.
118 Fortunately, clinical trials with IAP antagonists
did not show any dose-limiting toxicity till date.
24
Insummary,a movetowards IAP antagonist-based therapy
should be pursued with caution as we still need better
understanding of the complex signaling interplay in context
of particular tumor types by using improved and multiple
model systems. Further, as there might be a chance
of enhanced cell migration and motility upon IAP inhibition in
surviving tumor cells, enhancing the apoptotic potential and
hampering the migratory potential of IAP antagonists by using
cell death inducers and Pak1 antagonists, respectively, in
combination promises to be a viable anticancer therapy.
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